At the time, use of SGLT2 inhibitors and GLP-1 receptor agonists in the UK was generally restricted to patients with type 2 diabetes, heart failure with reduced ejection fraction, or obesity, which may have constrained access in this cohort. Here, SLC5A2 is linked to obesity disorder.